Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
25.89
-1.10 (-4.08%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Mineralys Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Mineralys Therapeutics stock have an average target of 48.67, with a low estimate of 26 and a high estimate of 56. The average target predicts an increase of 87.99% from the current stock price of 25.89.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 13, 2026.
Analyst Ratings
The average analyst rating for Mineralys Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 4 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Apr 27, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $46 → $51 | Strong Buy | Maintains | $46 → $51 | +96.99% | Mar 13, 2026 |
| Stifel | Stifel | Strong Buy Maintains $45 → $52 | Strong Buy | Maintains | $45 → $52 | +100.85% | Dec 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $52 → $56 | Strong Buy | Maintains | $52 → $56 | +116.30% | Nov 12, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $50 → $55 | Buy | Maintains | $50 → $55 | +112.44% | Nov 11, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
120.36M
EPS This Year
-2.06
from -2.29
EPS Next Year
-1.90
from -2.06
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 426.1M | ||||||
| Avg | n/a | 120.4M | ||||||
| Low | n/a | 31.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.58 | 1.06 | ||||||
| Avg | -2.06 | -1.90 | ||||||
| Low | -2.36 | -2.69 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.